JP2024537906A - 粘膜炎を処置するための組成物及び方法 - Google Patents

粘膜炎を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2024537906A
JP2024537906A JP2024523414A JP2024523414A JP2024537906A JP 2024537906 A JP2024537906 A JP 2024537906A JP 2024523414 A JP2024523414 A JP 2024523414A JP 2024523414 A JP2024523414 A JP 2024523414A JP 2024537906 A JP2024537906 A JP 2024537906A
Authority
JP
Japan
Prior art keywords
human subject
mucositis
treating
oral
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537906A5 (https=
Inventor
キ ヨン ソン，
ソン ヨン ユン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzychem Lifesciences Corp
Original Assignee
Enzychem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzychem Lifesciences Corp filed Critical Enzychem Lifesciences Corp
Publication of JP2024537906A publication Critical patent/JP2024537906A/ja
Publication of JP2024537906A5 publication Critical patent/JP2024537906A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024523414A 2021-10-18 2022-10-18 粘膜炎を処置するための組成物及び方法 Pending JP2024537906A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257099P 2021-10-18 2021-10-18
US63/257,099 2021-10-18
PCT/IB2022/060007 WO2023067501A1 (en) 2021-10-18 2022-10-18 Compositions and methods for treating mucositis

Publications (2)

Publication Number Publication Date
JP2024537906A true JP2024537906A (ja) 2024-10-16
JP2024537906A5 JP2024537906A5 (https=) 2025-10-27

Family

ID=86057963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523414A Pending JP2024537906A (ja) 2021-10-18 2022-10-18 粘膜炎を処置するための組成物及び方法

Country Status (5)

Country Link
US (1) US20240415798A1 (https=)
EP (1) EP4419096A4 (https=)
JP (1) JP2024537906A (https=)
KR (1) KR20240089762A (https=)
WO (1) WO2023067501A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5026655B2 (ja) * 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
IL274974B2 (en) * 2017-11-30 2025-03-01 Enzychem Lifesciences Corp Compositions for prevention or treatment of acute radiation syndrome

Also Published As

Publication number Publication date
US20240415798A1 (en) 2024-12-19
WO2023067501A1 (en) 2023-04-27
EP4419096A4 (en) 2026-04-15
EP4419096A1 (en) 2024-08-28
KR20240089762A (ko) 2024-06-20

Similar Documents

Publication Publication Date Title
Pfaffenrath et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension‐type headache: a multi‐centre controlled study
JP2016188214A (ja) グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
JP7125353B2 (ja) Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
Storms et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
Passali et al. Pidotimod in the management of recurrent pharyngotonsillar infections in childhood
CN112638378A (zh) 用于根除幽门螺杆菌的组合物
WO2021142030A1 (en) Methods of treating conditions related to the s1p1 receptor
KR102053208B1 (ko) 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
JP2022500485A (ja) グラピプラント単位剤形
JP2024537906A (ja) 粘膜炎を処置するための組成物及び方法
US20230330054A1 (en) Method for preventing or treating lung infection and lung inflammation
JP6912875B2 (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
EP3646864A1 (en) Pharmaceutical containing pemafibrate
WO2021161983A1 (en) Novel medicament for treating inflammatory disease
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
Genovese et al. SAT0089 Safety and efficacy of LY3337641, a Bruton's tyrosine kinase inhibitor in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase 2 study
CN109939223B (zh) 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療
HK40125990A (zh) 对心律无显着影响的库欣综合征的治疗
RU2391984C1 (ru) Способ лечения акантолитической пузырчатки
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
WO2022045673A1 (ko) 신규한 화합물을 유효성분으로 포함하는 심근경색 후 심부전 예방 또는 치료용 조성물 및 이의 용도
Laine et al. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation
CN119214315A (zh) 一种用于预防和/或治疗肿瘤病人化疗引发的周围神经病变的配方产品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017